Identification and validation of TSPAN13 as a novel temozolomide resistance-related gene prognostic biomarker in glioblastoma.
Glioblastoma (GBM) is the most lethal primary tumor of the central nervous system, with its resistance to treatment posing significant challenges. This study aims to develop a comprehensive prognostic model to identify biomarkers associated with temozolomide (TMZ) resistance. We employed a multiface...
Saved in:
Main Authors: | Haofei Wang, Zhen Liu, Zesheng Peng, Peng Lv, Peng Fu, Xiaobing Jiang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2025-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0316552 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Associated adverse outcomes with tumor treating fields when combined to temozolomide versus temozolomide alone for the treatment of glioblastoma: a meta-analysis of randomized trials
by: Yuanyuan Chen, et al.
Published: (2025-02-01) -
Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment.
by: Artem Berezovsky, et al.
Published: (2025-01-01) -
NOS2 as a prognostic biomarker for early-onset colorectal cancer based on public data and clinical validation analysis
by: Chaoqun Xing, et al.
Published: (2025-02-01) -
Deciphering the Immune Subtypes and Signature Genes: A Novel Approach Towards Diagnosing and Prognosticating Severe Asthma Through Interpretable Machine Learning
by: Yue Hu, et al.
Published: (2024-01-01) -
Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastoma
by: Douglas A Lauffenburger, et al.
Published: (2025-02-01)